Axsome Therapeutics, Inc. (AXSM)
183.72
-2.46
(-1.32%)
USD |
NASDAQ |
Feb 20, 16:00
183.96
+0.24
(+0.13%)
After-Hours: 20:00
Axsome Therapeutics Research and Development Expense (Quarterly) : 40.04M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 68.85M |
| Gilead Sciences, Inc. | 1.565B |
| Vanda Pharmaceuticals, Inc. | 29.01M |
| ACADIA Pharmaceuticals, Inc. | 87.83M |
| Amicus Therapeutics, Inc. | -- |